Mission impossible: How HPV-associated head and neck cancers escape a primed immune response

Oral Oncology

Volumn 49, Issue 8, 2013, Pages 723-725

  Pai, Sara I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB;

ANTIGEN RECOGNITION; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; EDITORIAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNE RESPONSE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; WART VIRUS;

ALPHAPAPILLOMAVIRUS; HEAD AND NECK NEOPLASMS; HUMANS; TUMOR ESCAPE;

EID: 84880062401     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.03.453     Document Type: Editorial

References (9)

1. A.K. Chaturvedi, E.A. Engels, R.M. Pfeiffer, B.Y. Hernandez, W. Xiao, and E. Kim Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 10 29(32) 2011 4294 4301
2. W.H. Westra The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer Head Neck Pathol 1 2009 78 81
3. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res, January 3; 2013 [Epub ahead of print].
4. F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, and M. Ichikawa Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 3 2005 1089 1096
5. F. Porichis, D.S. Kwon, J. Zupkosky, D.P. Tighe, A. McMullen, and M.A. Brockman Responsiveness of HIV-specific CD4 T cells to PD-1 blockade Blood 118 4 2011 965 974
6. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilumimab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
7. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, and W.H. Sharfman Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 2167 2175
8. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Eng J Med 366 26 2012 2443 2454
9. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Eng J Med 366 26 2012 2455 2465